Published in J Immunother on June 11, 2016
Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT) | NCT02529072
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight (2017) 0.75
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide. J Immunother Cancer (2016) 0.75
Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN(®) (dendritic cell-based vaccine): a case report. Clin Case Rep (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 13.88
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res (2011) 2.20
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev (2003) 2.08
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Immune suppression in the tumor microenvironment. J Immunother (2006) 1.90
Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res (2009) 1.51
Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol (2015) 1.42
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35
Challenges of guarantee-time bias. J Clin Oncol (2013) 1.27
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 1.11
Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods (2002) 1.08
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood (2010) 1.07
Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res (2012) 1.03
In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res (2009) 1.02
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One (2013) 0.97
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clin Cancer Res (2015) 0.96
Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med (2005) 0.89
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. J Clin Oncol (2016) 0.89
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology (2015) 0.87
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology (2015) 0.85
Checkpoint blockade in combination with cancer vaccines. Vaccine (2015) 0.84
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother (2016) 0.81
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 3.85
Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev (2003) 2.52
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol (2003) 2.30
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J (2006) 2.20
Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology (2013) 2.17
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res (2004) 2.06
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol (2011) 2.06
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Myosin II and mechanotransduction: a balancing act. Trends Cell Biol (2007) 1.85
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 1.83
Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood (2011) 1.83
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
How C-type lectins detect pathogens. Cell Microbiol (2005) 1.77
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat (2010) 1.75
Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer (2012) 1.73
Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem (2002) 1.71
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol (2005) 1.70
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med (2010) 1.68
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther (2010) 1.67
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med (2010) 1.60
Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. Proc Natl Acad Sci U S A (2009) 1.60
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol (2003) 1.53
Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J Biol Chem (2008) 1.50
(19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol (2010) 1.49
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol (2005) 1.48
Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J Cell Biol (2004) 1.48
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 1.41
Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta (2010) 1.40
The heme-heme oxygenase system: a molecular switch in wound healing. Blood (2003) 1.39
The small GTPase Rap1 is required for Mn(2+)- and antibody-induced LFA-1- and VLA-4-mediated cell adhesion. J Biol Chem (2002) 1.39
A critical role for prostaglandin E2 in podosome dissolution and induction of high-speed migration during dendritic cell maturation. J Immunol (2006) 1.37
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2005) 1.36
MicroRNAs in colorectal cancer metastasis. J Pathol (2011) 1.36
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol (2012) 1.34
The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood (2012) 1.34
Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology (2008) 1.33
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother (2012) 1.32
TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation. J Mol Biol (2008) 1.32